Clinical Trial

Recombinant Influenza Vaccination in U.S. Nursing Homes

Study Description

Recombinant Influenza Vaccination in U.S. Nursing Homes

Based on recent evidence on the mutation of the A/H3N2 strain in egg-grown vaccine, the investigators will study the quadrivalent recombinant influenza vaccine (RIV4, Flublok) compared to the standard dose quadrivalent vaccine (IV4) in a cohort of long-stay NH residents with a primary endpoint of all-cause respiratory-related hospitalization.

Location

Locations Selected Location

Methods

No pharmaceutical medication involved No pharmaceutical medication involved
Patients and healthy individuals accepted Patients and healthy individuals accepted

Biological - Recombinant Influenza Vaccine

Nursing home residents and staff 18 years and older are allocated to receive quadrivalent recombinant influenza vaccine.

Biological - Standard Dose Quadrivalent Influenza Vaccine

Nursing home residents and staff 18 years and older are allocated to receive standard dose quadrivalent influenza vaccine

Additional Information

Official Study Title

Comparative Effectiveness of Recombinant Versus Standard Dose Quadrivalent Influenza Vaccine in U.S. Nursing Homes

Clinical Trial ID

NCT03965195

ParticipAid ID

dJ6xKd